| [1] |
Lee YH, Baek JH, Jung SL, et al. Ultrasound-guided fine needle aspiration of thyroid nodules: a consensus statement by the korean society of thyroid radiology [J]. Korean J Radiol, 2015, 16(2): 391-401.
|
| [2] |
Krishnappa P, Ramakrishnappa S, Kulkarni MH. Comparison of free hand versus ultrasound-guided fine needle aspiration of thyroid with histopathological correlation [J]. J Environ Pathol Toxicol Oncol, 2013, 32(2): 149-155.
|
| [3] |
张少航, 牛丽娟. 超声引导下穿刺粗针病理学和细胞学及细针细胞学在甲状腺微小结节中的诊断价值[J]. 中华耳鼻咽喉头颈外科杂志, 2014, 49(11): 893-896.
|
| [4] |
Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer [J]. Thyroid, 2009, 19(11): 1167-1214.
|
| [5] |
Gharib H, Papini E, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations [J]. J Endocrinol Invest, 2010, 33(5 Suppl): 51-56.
|
| [6] |
Guo HQ, Zhao H, Zhang ZH, et al. Impact of molecular testing in the diagnosis of thyroid fine needle aspiration cytology: data from mainland China [J]. Dis Markers, 2014: 912182
|
| [7] |
鲁海珍, 邱田, 应建明, 等. BRAF V600E突变与甲状腺乳头状癌临床病理特征的关系[J].中华病理学杂志, 2014, 43(12): 794-798
|
| [8] |
Kim SY, Kim EK, Kwak JY, et al. What to do with thyroid nodules showing benign cytology and BRAF(V600E) mutation? A study based on clinical and radiologic features using a highly sensitive analytic method [J]. Surgery, 2015, 157(2): 354-361.
|
| [9] |
Seo JY, Choi JR, Moon HJ, et al. Clinical Implication of Highly Sensitive Detection of the BRAFV600E Mutation in Fine-Needle Aspirations According to the Thyroid Bethesda System in Patients With Conventional Papillary Thyroid Carcinoma [J]. Ann Otol Rhinol Laryngol, 2015, 124(5): 392-399.
|
| [10] |
Lu J, Gao J, Zhang J, et al. Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma [J]. Int J Clin Exp Pathol, 2015, 8(1): 793-799.
|
| [11] |
Das DK, Al-WaheebSK, George SS, et al. Contribution of immunocytochemical stainings for galectin-3, CD44, and HBME1 to fine-needle aspiration cytology diagnosis of papillary thyroid carcinoma [J]. Diagn Cytopathol, 2014, 42(6): 498-505.
|
| [12] |
Dencic TM, Savin SB, Selemetjev SA, et al. Strong Expression of HBME-1 Associates with High-Risk Clinicopathological Factors of Papillary Thyroid Carcinoma [J]. Pathol Oncol Res, 2015, 21(3): 735-742.
|
| [13] |
Ma H, Xu S, Yan J, et al. The value of tumor markers in the diagnosis of papillary thyroid carcinoma alone and in combination [J]. Pol J Pathol, 2014, 65(3): 202-209.
|
| [14] |
Camargo BM, Albuquerque MF, Pinto CA, et al. High diagnostic accuracy based on CLDN10, HMGA2 and LAMB3 transcripts in papillary thyroid carcinoma [J]. J Clin Endocrinol Metab, 2015, 100(6): E890-899.
|
| [15] |
Aliyev A, Gupta M, Nasr C, et al. Circulating Thyrotropin Receptor Messenger RNA as a Marker of Tumor Aggressiveness in Patients with Papillary Thyroid Microcarcinoma [J]. Endocr Pract, 2015, 21(7): 777-781.
|
| [16] |
Sheahan P, Mohamed M, Ryan C, et al. Follicular variant of papillary thyroid carcinoma: differences from conventional disease in cytologic findings and high-risk features [J]. JAMA Otolaryngol Head Neck Surg, 2014, 140(12): 1117-1123.
|
| [17] |
Finnerty BM, Kleiman DA, Scognamiglio T, et al. Navigating the management of follicular variant papillary thyroid carcinoma subtypes: a classic PTC comparison [J]. Ann Surg Oncol, 2015, 22(4): 1200-1206.
|
| [18] |
Walts AE, Mirocha JM, Bose S. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status [J]. J Cancer Res Clin Oncol, 2015, 141(10): 1749-1756.
|
| [19] |
Lee SR, Jung CK, Kim TE, et al. Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing [J]. Thyroid, 2013, 23(11): 1416-1422.
|
| [20] |
Armstrong MJ, Yang H, Yip L, et al. PAX8/PPARgamma rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma [J]. Thyroid, 2014, 24(9): 1369-1374.
|
| [21] |
Ohta M, Ookoshi T, Naiki H, et al. HBME-1 and CD15 immunocytochemistry in the follicular variant of thyroid papillary carcinoma [J]. Pathol Int, 2015, 65(3): 119-125.
|
| [22] |
Aboelnaga EM, Ahmed RA. Difference between papillary and follicular thyroid carcinoma outcomes: an experience from Egyptian institution [J]. Cancer Biol Med, 2015, 12(1): 53-59.
|
| [23] |
Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology [J]. Thyroid, 2009, 19(11): 1159-1165.
|
| [24] |
Lacoste-Collin L, d'Aure D, Berard E, et al. Improvement of the cytological diagnostic accuracy of follicular thyroid lesions by the use of the Ki-67 proliferative index in addition to cytokeratin-19 and HBME-1 immunomarkers: a study of 61 cases of liquid-based FNA cytology with histological controls [J]. Cytopathology, 2014, 25(3): 160-169.
|
| [25] |
Wang N, Liu T, Sofiadis A, et al. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA [J]. Cancer, 2014, 120(19): 2965-2979.
|
| [26] |
Jang MH, Jung KC, Min HS. The Diagnostic Usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 delta in Follicular Thyroid Carcinoma [J]. J Pathol Transl Med, 2015, 49(2): 112-117.
|
| [27] |
Jang EK, Song DE, Sim SY, et al. NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma [J]. Thyroid, 2014, 24(8): 1275-1281.
|
| [28] |
Sahpaz A, Onal B, Yesilyurt A, et al. BRAF(V600E) Mutation, RET/PTC1 and PAX8-PPAR Gamma Rearrangements in Follicular Epithelium Derived Thyroid Lesions - Institutional Experience and Literature Review [J]. Balkan Med J, 2015, 32(2): 156-166.
|
| [29] |
Mochizuki K, Kondo T, Oishi N, et al. Low frequency of PAX8-PPARgamma rearrangement in follicular thyroid carcinomas in Japanese patients [J]. Pathol Int, 2015, 65(5): 250-3.
|
| [30] |
Yeganeh MZ, Sheikholeslami S, Hedayati M. RET Proto Oncogene Mutation Detection and Medullary Thyroid Carcinoma Prevention [J]. Asian Pac J Cancer Prev, 2015, 16(6): 2107-2117.
|
| [31] |
Romei C, Tacito A, Molinaro E, et al. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer [J]. Clin Endocrinol (Oxf), 2014, 82(6): 892-899.
|
| [32] |
Colombo C, Minna E, Rizzetti MG, et al. The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies [J]. Orphanet J Rare Dis, 2015, 10(1): 25.
|
| [33] |
Ragazzi M, Ciarrocchi A, Sancisi V, et al. Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer [J]. Int J Endocrinol, 2014, 2014: 790834.
|
| [34] |
Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer [J]. N Engl J Med, 2013, 368(7): 684-685.
|
| [35] |
Gauchotte G, Philippe C, Lacomme S, et al. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis [J]. Pathology, 2011, 43(5): 447-452.
|
| [36] |
Stokowy T, Wojtas B, Fujarewicz K, et al. miRNAs with the potential to distinguish follicular thyroid carcinomas from benign follicular thyroid tumors: results of a meta-analysis [J]. Horm Metab Res, 2014, 46(3): 171-180.
|
| [37] |
Zhang Y, Zhong Q, Chen X, et al. Diagnostic value of microRNAs in discriminating malignant thyroid nodules from benign ones on fine-needle aspiration samples [J]. Tumour Biol, 2014, 35(9): 9343-9353.
|
| [38] |
Ali SZ, Fish SA, Lanman R, et al. Use of the afirma(R) gene expression classifier for preoperative identification of benign thyroid nodules with indeterminate fine needle aspiration cytopathology [J]. PLoS Curr, 2013: 5.
|
| [39] |
Kloos RT, Reynolds JD, Walsh PS, et al. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules [J]. J Clin Endocrinol Metab, 2013, 98(4): E761-E768.
|
| [40] |
Marti JL, Avadhani V, Donatelli LA, et al. Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules [J]. Ann Surg Oncol, 2015. [Epub ahead of print]
|